The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study

Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI),...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Flora N. Balieva [verfasserIn] Andrew Y. Finlay [verfasserIn] Jörg Kupfer [verfasserIn] Lucía Tomas Aragones [verfasserIn] Lars Lien [verfasserIn] Uwe Gieler [verfasserIn] Françoise Poot [verfasserIn] Gregor B. E. Jemec [verfasserIn] Laurent Misery [verfasserIn] Lajos Kemeny [verfasserIn] Francesca Sampogna [verfasserIn] Henriët van Middendorp [verfasserIn] Jon Anders Halvorsen [verfasserIn] Thomas Ternowitz [verfasserIn] Jacek C. Szepietowski [verfasserIn] Nikolay Potekaev [verfasserIn] Servando E. Marron [verfasserIn] Ilknur K. Altunay [verfasserIn] Sam S. Salek [verfasserIn] Florence J. Dalgard [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2018

Schlagwörter:	qualityoflife HRQoL DLQI dermatologicaltherapy burdenofskindisease therapyburden

Übergeordnetes Werk:	In: Acta Dermato-Venereologica - Medical Journals Sweden, 2011, 98(2018), 6, Seite 563-569
Übergeordnetes Werk:	volume:98 ; year:2018 ; number:6 ; pages:563-569

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.2340/00015555-2918

Katalog-ID:	DOAJ07160118X

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ07160118X
003	DE-627
005	20230309102522.0
007	cr uuu---uuuuu
008	230228s2018 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.2340/00015555-2918 \|2 doi
035			\|a (DE-627)DOAJ07160118X
035			\|a (DE-599)DOAJ3bfe3b4153a74625b32e859e34803b11
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RL1-803
100	0		\|a Flora N. Balieva \|e verfasserin \|4 aut
245	1	4	\|a The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study
264		1	\|c 2018
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies.
650		4	\|a qualityoflife
650		4	\|a HRQoL
650		4	\|a DLQI
650		4	\|a dermatologicaltherapy
650		4	\|a burdenofskindisease
650		4	\|a therapyburden
653		0	\|a Dermatology
700	0		\|a Andrew Y. Finlay \|e verfasserin \|4 aut
700	0		\|a Jörg Kupfer \|e verfasserin \|4 aut
700	0		\|a Lucía Tomas Aragones \|e verfasserin \|4 aut
700	0		\|a Lars Lien \|e verfasserin \|4 aut
700	0		\|a Uwe Gieler \|e verfasserin \|4 aut
700	0		\|a Françoise Poot \|e verfasserin \|4 aut
700	0		\|a Gregor B. E. Jemec \|e verfasserin \|4 aut
700	0		\|a Laurent Misery \|e verfasserin \|4 aut
700	0		\|a Lajos Kemeny \|e verfasserin \|4 aut
700	0		\|a Francesca Sampogna \|e verfasserin \|4 aut
700	0		\|a Henriët van Middendorp \|e verfasserin \|4 aut
700	0		\|a Jon Anders Halvorsen \|e verfasserin \|4 aut
700	0		\|a Thomas Ternowitz \|e verfasserin \|4 aut
700	0		\|a Jacek C. Szepietowski \|e verfasserin \|4 aut
700	0		\|a Nikolay Potekaev \|e verfasserin \|4 aut
700	0		\|a Servando E. Marron \|e verfasserin \|4 aut
700	0		\|a Ilknur K. Altunay \|e verfasserin \|4 aut
700	0		\|a Sam S. Salek \|e verfasserin \|4 aut
700	0		\|a Florence J. Dalgard \|e verfasserin \|4 aut
773	0	8	\|i In \|t Acta Dermato-Venereologica \|d Medical Journals Sweden, 2011 \|g 98(2018), 6, Seite 563-569 \|w (DE-627)302725431 \|w (DE-600)1492617-9 \|x 16512057 \|7 nnns
773	1	8	\|g volume:98 \|g year:2018 \|g number:6 \|g pages:563-569
856	4	0	\|u https://doi.org/10.2340/00015555-2918 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/3bfe3b4153a74625b32e859e34803b11 \|z kostenfrei
856	4	0	\|u https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2918 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/0001-5555 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1651-2057 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 98 \|j 2018 \|e 6 \|h 563-569

Indexfelder

author_variant	f n b fnb a y f ayf j k jk l t a lta l l ll u g ug f p fp g b e j gbej l m lm l k lk f s fs h v m hvm j a h jah t t tt j c s jcs n p np s e m sem i k a ika s s s sss f j d fjd
matchkey_str	article:16512057:2018----::hrloteaynmarnqaiyfienemtlgclai
hierarchy_sort_str	2018
callnumber-subject-code	RL
publishDate	2018
allfields	10.2340/00015555-2918 doi (DE-627)DOAJ07160118X (DE-599)DOAJ3bfe3b4153a74625b32e859e34803b11 DE-627 ger DE-627 rakwb eng RL1-803 Flora N. Balieva verfasserin aut The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies. qualityoflife HRQoL DLQI dermatologicaltherapy burdenofskindisease therapyburden Dermatology Andrew Y. Finlay verfasserin aut Jörg Kupfer verfasserin aut Lucía Tomas Aragones verfasserin aut Lars Lien verfasserin aut Uwe Gieler verfasserin aut Françoise Poot verfasserin aut Gregor B. E. Jemec verfasserin aut Laurent Misery verfasserin aut Lajos Kemeny verfasserin aut Francesca Sampogna verfasserin aut Henriët van Middendorp verfasserin aut Jon Anders Halvorsen verfasserin aut Thomas Ternowitz verfasserin aut Jacek C. Szepietowski verfasserin aut Nikolay Potekaev verfasserin aut Servando E. Marron verfasserin aut Ilknur K. Altunay verfasserin aut Sam S. Salek verfasserin aut Florence J. Dalgard verfasserin aut In Acta Dermato-Venereologica Medical Journals Sweden, 2011 98(2018), 6, Seite 563-569 (DE-627)302725431 (DE-600)1492617-9 16512057 nnns volume:98 year:2018 number:6 pages:563-569 https://doi.org/10.2340/00015555-2918 kostenfrei https://doaj.org/article/3bfe3b4153a74625b32e859e34803b11 kostenfrei https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2918 kostenfrei https://doaj.org/toc/0001-5555 Journal toc kostenfrei https://doaj.org/toc/1651-2057 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 98 2018 6 563-569
spelling	10.2340/00015555-2918 doi (DE-627)DOAJ07160118X (DE-599)DOAJ3bfe3b4153a74625b32e859e34803b11 DE-627 ger DE-627 rakwb eng RL1-803 Flora N. Balieva verfasserin aut The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies. qualityoflife HRQoL DLQI dermatologicaltherapy burdenofskindisease therapyburden Dermatology Andrew Y. Finlay verfasserin aut Jörg Kupfer verfasserin aut Lucía Tomas Aragones verfasserin aut Lars Lien verfasserin aut Uwe Gieler verfasserin aut Françoise Poot verfasserin aut Gregor B. E. Jemec verfasserin aut Laurent Misery verfasserin aut Lajos Kemeny verfasserin aut Francesca Sampogna verfasserin aut Henriët van Middendorp verfasserin aut Jon Anders Halvorsen verfasserin aut Thomas Ternowitz verfasserin aut Jacek C. Szepietowski verfasserin aut Nikolay Potekaev verfasserin aut Servando E. Marron verfasserin aut Ilknur K. Altunay verfasserin aut Sam S. Salek verfasserin aut Florence J. Dalgard verfasserin aut In Acta Dermato-Venereologica Medical Journals Sweden, 2011 98(2018), 6, Seite 563-569 (DE-627)302725431 (DE-600)1492617-9 16512057 nnns volume:98 year:2018 number:6 pages:563-569 https://doi.org/10.2340/00015555-2918 kostenfrei https://doaj.org/article/3bfe3b4153a74625b32e859e34803b11 kostenfrei https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2918 kostenfrei https://doaj.org/toc/0001-5555 Journal toc kostenfrei https://doaj.org/toc/1651-2057 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 98 2018 6 563-569
allfields_unstemmed	10.2340/00015555-2918 doi (DE-627)DOAJ07160118X (DE-599)DOAJ3bfe3b4153a74625b32e859e34803b11 DE-627 ger DE-627 rakwb eng RL1-803 Flora N. Balieva verfasserin aut The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies. qualityoflife HRQoL DLQI dermatologicaltherapy burdenofskindisease therapyburden Dermatology Andrew Y. Finlay verfasserin aut Jörg Kupfer verfasserin aut Lucía Tomas Aragones verfasserin aut Lars Lien verfasserin aut Uwe Gieler verfasserin aut Françoise Poot verfasserin aut Gregor B. E. Jemec verfasserin aut Laurent Misery verfasserin aut Lajos Kemeny verfasserin aut Francesca Sampogna verfasserin aut Henriët van Middendorp verfasserin aut Jon Anders Halvorsen verfasserin aut Thomas Ternowitz verfasserin aut Jacek C. Szepietowski verfasserin aut Nikolay Potekaev verfasserin aut Servando E. Marron verfasserin aut Ilknur K. Altunay verfasserin aut Sam S. Salek verfasserin aut Florence J. Dalgard verfasserin aut In Acta Dermato-Venereologica Medical Journals Sweden, 2011 98(2018), 6, Seite 563-569 (DE-627)302725431 (DE-600)1492617-9 16512057 nnns volume:98 year:2018 number:6 pages:563-569 https://doi.org/10.2340/00015555-2918 kostenfrei https://doaj.org/article/3bfe3b4153a74625b32e859e34803b11 kostenfrei https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2918 kostenfrei https://doaj.org/toc/0001-5555 Journal toc kostenfrei https://doaj.org/toc/1651-2057 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 98 2018 6 563-569
allfieldsGer	10.2340/00015555-2918 doi (DE-627)DOAJ07160118X (DE-599)DOAJ3bfe3b4153a74625b32e859e34803b11 DE-627 ger DE-627 rakwb eng RL1-803 Flora N. Balieva verfasserin aut The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies. qualityoflife HRQoL DLQI dermatologicaltherapy burdenofskindisease therapyburden Dermatology Andrew Y. Finlay verfasserin aut Jörg Kupfer verfasserin aut Lucía Tomas Aragones verfasserin aut Lars Lien verfasserin aut Uwe Gieler verfasserin aut Françoise Poot verfasserin aut Gregor B. E. Jemec verfasserin aut Laurent Misery verfasserin aut Lajos Kemeny verfasserin aut Francesca Sampogna verfasserin aut Henriët van Middendorp verfasserin aut Jon Anders Halvorsen verfasserin aut Thomas Ternowitz verfasserin aut Jacek C. Szepietowski verfasserin aut Nikolay Potekaev verfasserin aut Servando E. Marron verfasserin aut Ilknur K. Altunay verfasserin aut Sam S. Salek verfasserin aut Florence J. Dalgard verfasserin aut In Acta Dermato-Venereologica Medical Journals Sweden, 2011 98(2018), 6, Seite 563-569 (DE-627)302725431 (DE-600)1492617-9 16512057 nnns volume:98 year:2018 number:6 pages:563-569 https://doi.org/10.2340/00015555-2918 kostenfrei https://doaj.org/article/3bfe3b4153a74625b32e859e34803b11 kostenfrei https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2918 kostenfrei https://doaj.org/toc/0001-5555 Journal toc kostenfrei https://doaj.org/toc/1651-2057 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 98 2018 6 563-569
allfieldsSound	10.2340/00015555-2918 doi (DE-627)DOAJ07160118X (DE-599)DOAJ3bfe3b4153a74625b32e859e34803b11 DE-627 ger DE-627 rakwb eng RL1-803 Flora N. Balieva verfasserin aut The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies. qualityoflife HRQoL DLQI dermatologicaltherapy burdenofskindisease therapyburden Dermatology Andrew Y. Finlay verfasserin aut Jörg Kupfer verfasserin aut Lucía Tomas Aragones verfasserin aut Lars Lien verfasserin aut Uwe Gieler verfasserin aut Françoise Poot verfasserin aut Gregor B. E. Jemec verfasserin aut Laurent Misery verfasserin aut Lajos Kemeny verfasserin aut Francesca Sampogna verfasserin aut Henriët van Middendorp verfasserin aut Jon Anders Halvorsen verfasserin aut Thomas Ternowitz verfasserin aut Jacek C. Szepietowski verfasserin aut Nikolay Potekaev verfasserin aut Servando E. Marron verfasserin aut Ilknur K. Altunay verfasserin aut Sam S. Salek verfasserin aut Florence J. Dalgard verfasserin aut In Acta Dermato-Venereologica Medical Journals Sweden, 2011 98(2018), 6, Seite 563-569 (DE-627)302725431 (DE-600)1492617-9 16512057 nnns volume:98 year:2018 number:6 pages:563-569 https://doi.org/10.2340/00015555-2918 kostenfrei https://doaj.org/article/3bfe3b4153a74625b32e859e34803b11 kostenfrei https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2918 kostenfrei https://doaj.org/toc/0001-5555 Journal toc kostenfrei https://doaj.org/toc/1651-2057 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 98 2018 6 563-569
language	English
source	In Acta Dermato-Venereologica 98(2018), 6, Seite 563-569 volume:98 year:2018 number:6 pages:563-569
sourceStr	In Acta Dermato-Venereologica 98(2018), 6, Seite 563-569 volume:98 year:2018 number:6 pages:563-569
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	qualityoflife HRQoL DLQI dermatologicaltherapy burdenofskindisease therapyburden Dermatology
isfreeaccess_bool	true
container_title	Acta Dermato-Venereologica
authorswithroles_txt_mv	Flora N. Balieva @@aut@@ Andrew Y. Finlay @@aut@@ Jörg Kupfer @@aut@@ Lucía Tomas Aragones @@aut@@ Lars Lien @@aut@@ Uwe Gieler @@aut@@ Françoise Poot @@aut@@ Gregor B. E. Jemec @@aut@@ Laurent Misery @@aut@@ Lajos Kemeny @@aut@@ Francesca Sampogna @@aut@@ Henriët van Middendorp @@aut@@ Jon Anders Halvorsen @@aut@@ Thomas Ternowitz @@aut@@ Jacek C. Szepietowski @@aut@@ Nikolay Potekaev @@aut@@ Servando E. Marron @@aut@@ Ilknur K. Altunay @@aut@@ Sam S. Salek @@aut@@ Florence J. Dalgard @@aut@@
publishDateDaySort_date	2018-01-01T00:00:00Z
hierarchy_top_id	302725431
id	DOAJ07160118X
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ07160118X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309102522.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2018 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2340/00015555-2918</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ07160118X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ3bfe3b4153a74625b32e859e34803b11</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RL1-803</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Flora N. Balieva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">qualityoflife</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HRQoL</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">DLQI</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dermatologicaltherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">burdenofskindisease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">therapyburden</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dermatology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrew Y. Finlay</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jörg Kupfer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lucía Tomas Aragones</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lars Lien</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Uwe Gieler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Françoise Poot</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gregor B. E. Jemec</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Laurent Misery</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lajos Kemeny</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesca Sampogna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Henriët van Middendorp</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jon Anders Halvorsen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thomas Ternowitz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jacek C. Szepietowski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nikolay Potekaev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Servando E. Marron</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ilknur K. Altunay</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sam S. Salek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Florence J. Dalgard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Acta Dermato-Venereologica</subfield><subfield code="d">Medical Journals Sweden, 2011</subfield><subfield code="g">98(2018), 6, Seite 563-569</subfield><subfield code="w">(DE-627)302725431</subfield><subfield code="w">(DE-600)1492617-9</subfield><subfield code="x">16512057</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:98</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:563-569</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.2340/00015555-2918</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/3bfe3b4153a74625b32e859e34803b11</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2918</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0001-5555</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1651-2057</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">98</subfield><subfield code="j">2018</subfield><subfield code="e">6</subfield><subfield code="h">563-569</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Flora N. Balieva
spellingShingle	Flora N. Balieva misc RL1-803 misc qualityoflife misc HRQoL misc DLQI misc dermatologicaltherapy misc burdenofskindisease misc therapyburden misc Dermatology The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study
authorStr	Flora N. Balieva
ppnlink_with_tag_str_mv	@@773@@(DE-627)302725431
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RL1-803
illustrated	Not Illustrated
issn	16512057
topic_title	RL1-803 The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study qualityoflife HRQoL DLQI dermatologicaltherapy burdenofskindisease therapyburden
topic	misc RL1-803 misc qualityoflife misc HRQoL misc DLQI misc dermatologicaltherapy misc burdenofskindisease misc therapyburden misc Dermatology
topic_unstemmed	misc RL1-803 misc qualityoflife misc HRQoL misc DLQI misc dermatologicaltherapy misc burdenofskindisease misc therapyburden misc Dermatology
topic_browse	misc RL1-803 misc qualityoflife misc HRQoL misc DLQI misc dermatologicaltherapy misc burdenofskindisease misc therapyburden misc Dermatology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Acta Dermato-Venereologica
hierarchy_parent_id	302725431
hierarchy_top_title	Acta Dermato-Venereologica
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)302725431 (DE-600)1492617-9
title	The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study
ctrlnum	(DE-627)DOAJ07160118X (DE-599)DOAJ3bfe3b4153a74625b32e859e34803b11
title_full	The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study
author_sort	Flora N. Balieva
journal	Acta Dermato-Venereologica
journalStr	Acta Dermato-Venereologica
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2018
contenttype_str_mv	txt
container_start_page	563
author_browse	Flora N. Balieva Andrew Y. Finlay Jörg Kupfer Lucía Tomas Aragones Lars Lien Uwe Gieler Françoise Poot Gregor B. E. Jemec Laurent Misery Lajos Kemeny Francesca Sampogna Henriët van Middendorp Jon Anders Halvorsen Thomas Ternowitz Jacek C. Szepietowski Nikolay Potekaev Servando E. Marron Ilknur K. Altunay Sam S. Salek Florence J. Dalgard
container_volume	98
class	RL1-803
format_se	Elektronische Aufsätze
author-letter	Flora N. Balieva
doi_str_mv	10.2340/00015555-2918
author2-role	verfasserin
title_sort	role of therapy in impairing quality of life in dermatological patients: a multinational study
callnumber	RL1-803
title_auth	The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study
abstract	Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies.
abstractGer	Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies.
abstract_unstemmed	Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	6
title_short	The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study
url	https://doi.org/10.2340/00015555-2918 https://doaj.org/article/3bfe3b4153a74625b32e859e34803b11 https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2918 https://doaj.org/toc/0001-5555 https://doaj.org/toc/1651-2057
remote_bool	true
author2	Andrew Y. Finlay Jörg Kupfer Lucía Tomas Aragones Lars Lien Uwe Gieler Françoise Poot Gregor B. E. Jemec Laurent Misery Lajos Kemeny Francesca Sampogna Henriët van Middendorp Jon Anders Halvorsen Thomas Ternowitz Jacek C. Szepietowski Nikolay Potekaev Servando E. Marron Ilknur K. Altunay Sam S. Salek Florence J. Dalgard
author2Str	Andrew Y. Finlay Jörg Kupfer Lucía Tomas Aragones Lars Lien Uwe Gieler Françoise Poot Gregor B. E. Jemec Laurent Misery Lajos Kemeny Francesca Sampogna Henriët van Middendorp Jon Anders Halvorsen Thomas Ternowitz Jacek C. Szepietowski Nikolay Potekaev Servando E. Marron Ilknur K. Altunay Sam S. Salek Florence J. Dalgard
ppnlink	302725431
callnumber-subject	RL - Dermatology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.2340/00015555-2918
callnumber-a	RL1-803
up_date	2024-07-03T21:10:02.906Z
_version_	1803593714668404736
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ07160118X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309102522.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2018 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2340/00015555-2918</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ07160118X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ3bfe3b4153a74625b32e859e34803b11</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RL1-803</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Flora N. Balieva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">qualityoflife</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HRQoL</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">DLQI</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dermatologicaltherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">burdenofskindisease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">therapyburden</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dermatology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrew Y. Finlay</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jörg Kupfer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lucía Tomas Aragones</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lars Lien</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Uwe Gieler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Françoise Poot</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gregor B. E. Jemec</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Laurent Misery</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lajos Kemeny</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesca Sampogna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Henriët van Middendorp</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jon Anders Halvorsen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thomas Ternowitz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jacek C. Szepietowski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nikolay Potekaev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Servando E. Marron</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ilknur K. Altunay</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sam S. Salek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Florence J. Dalgard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Acta Dermato-Venereologica</subfield><subfield code="d">Medical Journals Sweden, 2011</subfield><subfield code="g">98(2018), 6, Seite 563-569</subfield><subfield code="w">(DE-627)302725431</subfield><subfield code="w">(DE-600)1492617-9</subfield><subfield code="x">16512057</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:98</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:563-569</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.2340/00015555-2918</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/3bfe3b4153a74625b32e859e34803b11</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2918</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0001-5555</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1651-2057</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">98</subfield><subfield code="j">2018</subfield><subfield code="e">6</subfield><subfield code="h">563-569</subfield></datafield></record></collection>
score	7.399349

Nicht das Richtige dabei?

Schreiben Sie uns!

The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?